JP2025511402A - 癌を治療するための併用療法 - Google Patents

癌を治療するための併用療法 Download PDF

Info

Publication number
JP2025511402A
JP2025511402A JP2024559035A JP2024559035A JP2025511402A JP 2025511402 A JP2025511402 A JP 2025511402A JP 2024559035 A JP2024559035 A JP 2024559035A JP 2024559035 A JP2024559035 A JP 2024559035A JP 2025511402 A JP2025511402 A JP 2025511402A
Authority
JP
Japan
Prior art keywords
azd5305
pharma
acceptable salt
enzalutamide
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511402A5 (https=
JPWO2023194530A5 (https=
Inventor
キアーラ コスリッチ，サビーナ
アール アルバーテラ，マーク
エス ブラウン，ジェシカ
レオ，エリザベッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2025511402A publication Critical patent/JP2025511402A/ja
Publication of JP2025511402A5 publication Critical patent/JP2025511402A5/ja
Publication of JPWO2023194530A5 publication Critical patent/JPWO2023194530A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024559035A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511402A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
US63/362,613 2022-04-07
PCT/EP2023/059130 WO2023194530A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (3)

Publication Number Publication Date
JP2025511402A true JP2025511402A (ja) 2025-04-15
JP2025511402A5 JP2025511402A5 (https=) 2026-04-10
JPWO2023194530A5 JPWO2023194530A5 (https=) 2026-04-10

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559035A Pending JP2025511402A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250213556A1 (https=)
EP (1) EP4504182A1 (https=)
JP (1) JP2025511402A (https=)
KR (1) KR20240170957A (https=)
CN (1) CN119212702A (https=)
AU (1) AU2023250031A1 (https=)
CA (1) CA3254949A1 (https=)
IL (1) IL316017A (https=)
MX (1) MX2024012392A (https=)
TW (1) TW202404661A (https=)
WO (1) WO2023194530A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Also Published As

Publication number Publication date
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12
IL316017A (en) 2024-11-01
EP4504182A1 (en) 2025-02-12
CN119212702A (zh) 2024-12-27
TW202404661A (zh) 2024-02-01
WO2023194530A1 (en) 2023-10-12
US20250213556A1 (en) 2025-07-03
AU2023250031A1 (en) 2024-11-14
MX2024012392A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
JP2021504384A (ja) Ｌｓｚ１０２及びアルペリシブを含む医薬品の組合せ
TW202425976A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
JP2025511402A (ja) 癌を治療するための併用療法
JP2025511401A (ja) 癌を治療するための併用療法
US20250228847A1 (en) Combination therapy for treating cancer
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
AU2005269052A1 (en) Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
US20250170146A1 (en) Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
TW202600137A (zh) 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法
JP2025522390A (ja) 癌を処置するための併用療法
WO2025242217A1 (zh) 一种含噻吩并嘧啶化合物的药物组合物、其制备方法及用途
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
WO2009024820A2 (en) Therapeutic treatment 014

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402